Pelthos Therapeutics (NYSEAMERICAN:PTHS) Trading Up 4.7% – Should You Buy?

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) shot up 4.7% on Thursday . The company traded as high as $28.74 and last traded at $28.72. 41,818 shares changed hands during trading, an increase of 147% from the average session volume of 16,949 shares. The stock had previously closed at $27.42.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Cantor Fitzgerald assumed coverage on Pelthos Therapeutics in a report on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 price target for the company. Piper Sandler started coverage on Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 price target for the company. Oppenheimer lifted their price target on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Zacks Research upgraded Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $55.80.

Pelthos Therapeutics Trading Up 4.7%

The company has a debt-to-equity ratio of 1.41, a current ratio of 2.79 and a quick ratio of 1.86. The business’s fifty day simple moving average is $24.97. The company has a market cap of $99.95 million, a P/E ratio of -1.39 and a beta of 3.16.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The business had revenue of $10.91 million during the quarter. On average, equities analysts predict that Pelthos Therapeutics Inc. will post -11.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Pelthos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in PTHS. Ikarian Capital LLC boosted its holdings in Pelthos Therapeutics by 309.5% during the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after acquiring an additional 193,307 shares during the period. J. Goldman & Co LP acquired a new stake in Pelthos Therapeutics in the 4th quarter valued at about $2,418,000. Boothbay Fund Management LLC raised its position in Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock valued at $2,501,000 after purchasing an additional 59,435 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of Pelthos Therapeutics during the 4th quarter worth about $1,085,000. Finally, Diadema Partners LP raised its position in shares of Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after acquiring an additional 14,502 shares in the last quarter. 77.96% of the stock is owned by hedge funds and other institutional investors.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).